Skip to main content
Premium Trial:

Request an Annual Quote

DNAe Secures £25M Bank Facility for Point-of-Care Sepsis Dx

NEW YORK (GenomeWeb) – Infectious disease diagnostics firm DNAe today announced a bank facility of £25 million ($38.7 million) from Citibank, to fund the development of its point-of-care diagnostics for septic infections. The firm said it expects to conduct clinical trials in 2016 and launch its product in 2017. The funds will help DNAe finish its attempt to integrate its Genalysis DNA sequencing technology with its subsidiary DNA Electronics' Pathogen Capture System to create a blood test for serious infections that provides results in two to three hours, the firm said in a statement.

In January, DNAe raised $24 million to acquire Albuquerque, New Mexico-based DNA Electronics, then known as nanoMR. DNAe's sequencing technology is the core of Thermo Fisher Scientific's Ion Torrent next-generation sequencing system.

"The development of our serious bloodstream infections test is progressing well," DNAe Executive Chairman Chris Toumazou said in a statement. "[W]e are in a great position to achieve our objective to launch our in vitro diagnostic system in 2017." He added that the company's technology "has the potential to revolutionize how patients with these life-threatening infections are treated and the bank facility demonstrates the confidence of the bank and of our shareholders in DNAe's technology, team, and strategy to achieve this."

The Scan

RNA Editing in Octopuses Seems to Help Acclimation to Shifts in Water Temperature

A paper in Cell reports that octopuses use RNA editing to help them adjust to different water temperatures.

Topical Compound to Block EGFR Inhibitors May Ease Skin Toxicities, Study Finds

A topical treatment described in Science Translational Medicine may limit skin toxicities seen with EGFR inhibitor therapy.

Dozen Genetic Loci Linked to Preeclampsia Risk in New GWAS

An analysis of genome-wide association study data in JAMA Cardiology finds genetic loci linked to preeclampsia that have ties to blood pressure.

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.